are you "in"? Join us at the next biomedley gathering

Senior and C-Level executives from the Biotech, Life Science and Medical Device industries gathering quarterly for fireside chats -- live, in person and totally off the record.  We last gathered on Wed Oct 25, 2023  featuring some of the local stars of biotech. KTLA Anchor and Breast Cancer Survivor Sandra Mitchell anchored our conversations with Tom Zindrick, CEO, Genelux (NASDAQ:GNLX), a veteran biotech industry leader, spending 16 years at Amgen and serving on other biotech companies’ boards of directors; David J. Whelan, CEO, BioscienceLA –  the innovation catalyst for life sciences in the region, accelerating the growth of funding, space, and talent ; and Vanessa Belozeroff, AVP, Organon (NYSE:OGN) Organon is the $6.5 bil pharma co focused on women’s health. Vanessa spent 18 years at Amgen.  

RSVP Now to join us at the next BioMedLey on Oct 25 featuring some of the local stars of biotech KTLA Anchor and Breast Cancer Survivor Sandra Mitchell who will anchor our conversations with Tom Zindrick, CEO, Genelux (NASDAQ:GNLX), a veteran biotech industry leader, spending 16 years at Amgen and serving on other biotech companies’ boards of directors; David J. Whelan, CEO, BioscienceLA –  the innovation catalyst for life sciences in the region, accelerating the growth of funding, space, and talent ; and Vanessa Belozeroff, AVP, Organon (NYSE:OGN) Organon is the $6.5 bil pharma co focused on women’s health. Vanessa spent 18 years at Amgen.  And as always we’ll have fine classical music performed by our favorite local artists during our reception in a private home, with fine wine and world class appetizers.

  BioMedLey gathered Sept 20, 2022 at UBS's Ryan Bristol's beautiful home overlooking the Santa Monica Mountains from Thousand Oaks. early Tuesday, Sept 20, 2022

6 to 8 PM

BioMedLeyers met the leaders of our local biotech and life science communities over drinks, apps and a fireside chat with the one and only Jane Wells from CNBC (and a local TO resident).

This Private Event – Invitation Only -- featured Senior Leaders (Manager or above) in Biotech, Lifescience and Medical Device Companies. Featured Guests included: 

Peter Anastasiou, CEO, Capsida Biotherapeutics

Arianne Callender, Associate General Counsel,

Kite Pharma; Former Senior Counsel, Amgen and

David Lucas, COO at A2 Biotherapeutics

6-7 Reception with Tray Passed Appetizers and Drinks

7-8 Jane Wells and Local Biotech Leaders!

 The biotech and life science industry is thriving on the 101 Corridor from LA to Santa Barbara thanks to Amgen, Takeda, Westlake Village Biopartners, Arcutis, Atara, Dyve Biosciences,  Cure Pharmaceuticals, Kate Farms and other  leading companies in the region.  Join Jane Wells from CNBC as she interviews these leaders and hear great music from local musicians -- part of the symphony who continue to  help orchestrate a high quality of life here.  

Headliners:

• Dr. Sean Harper, MD -- Dr. Sean Harper was head of Research & Development at Amgen for many years. He’s been both a practicing physician and a research scientist.  At Westlake VIllage Biopartners Sean helps identify promising new therapies and launch companies to address unmet medical needs.
• Hosted by CNBC’s Jane Wells (local Thousand Oaks resident)
• Music Presented by local musicians

  BioMedLey gathered in early July at a Thousand Oaks brew pub.  It was a casual  “buy a drink and get to know” format featuring  the leaders of Arcutis Biotherapeutics.  Frank Watanabe, CEO; Mas Matsuta, General Counsel and Patricia Turney, COO.

We gathered for some great craft beer, wine and appetizers.    Cost to attend $44 - includes two drink tickets, hosted appetizers and a donation to Sophia's Buddies, with funds supporting the BioMedLey Triathlon Team pediatric cancer research at Children's Hospital Los Angeles.  

Private Event – Invitation Only  Senior Leaders (Manager or above) in Biotech and Medical Device Companies  

Snapshot Arcutis is public (NASDAQ: ARQT), approx 200 employees, based in Westlake Village.  It has completed Phase III clinical trials and is awaiting FDA review on its lead therapy for plaque psoriasis.